1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Mera Pharmaceuticals, Inc.

Mera Pharmaceuticals, Inc.

MRPI
Mera Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
55,730.00Market Cap
Mera Pharmaceuticals, Inc.
MRPI
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
TTM
FRC
- -
- -
- -
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.03
-0.04
-0.05
-0.05
-0.05
-0.04
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.02
-0.05
-0.06
-0.06
-0.04
-0.03
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.08
-0.11
-0.15
-0.15
-0.16
-0.18
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
-0.01
-0.02
-0.02
-0.02
Book Value per Share
0.01
- -
0.02
0.01
0.01
- -
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
38
45
53
76
101
113
309
398
427
468
482
506
517
547
548
548
548
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
- -
1
1
- -
- -
- -
1
1
- -
- -
- -
Sales/Revenue/Turnover
-13,005.29
-173,350.23
- -
-3,700
- -
-318.26
-989.79
-159.9
-3.51
-140.35
-117.62
-57.79
-48.2
-33.69
-82.14
-66.44
-66.44
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-2
-3
-4
-5
-4
-1
-2
-1
-1
-1
- -
-2
- -
-1
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-12,979.32
-172,999.35
- -
-4,100
- -
-396.22
-1,115.69
-235.91
-121.43
-336.55
-131.45
-68.51
-318.92
-32.2
-186.18
-62.02
-62.02
Profit Margin (%)
- -
-1
-1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
1
- -
1
- -
1
2
3
2
2
2
- -
- -
-1
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Apr'11
Jul'11
Oct'11
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
547
548
547
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Apr'11
Jul'11
Oct'11
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.78%
-10.08%
27.72%
Free Cash Flow
13.17%
23.65%
-47.59%
Net Income, GAAP
55.93%
98.14%
-65.1%
Sales/Revenue/Turnover
136.46%
0.5%
4.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Similar Companies
Genelux Corporation (GNLX)
Univo Pharmaceuticals Ltd (UNVO.TA)
Samsung Biologics Co.,Ltd. (207940.KS)
LexaGene Holdings Inc. (0V43.L)
Virax Biolabs Group Limited (VRAX)
Unity Biotechnology, Inc. (UNBX)
Business
Mera Pharmaceuticals, Inc. (MRPI) develops and commercializes innovative pharmaceutical products focused on treatments for central nervous system disorders, pain management, and rare diseases. The company offers a pipeline of proprietary drug candidates including MRPI-251, a novel non-opioid analgesic targeting neuropathic pain; MRPI-407, an advanced therapy for treatment-resistant depression; and MRPI-892, a breakthrough candidate for Parkinson's disease symptoms, along with supportive services such as clinical trial management and regulatory consulting. Operations span research and development, manufacturing partnerships, and commercialization efforts primarily in North America, with expanding clinical trials in Europe and Asia. Founded in 2018 and headquartered in San Diego, California, Mera Pharmaceuticals maintains strategic alliances with leading contract research organizations and biotech accelerators. Recent developments include a $25 million Series B funding round completed in March 2025 led by venture capital firms focused on neurology therapeutics; the acquisition of a Phase II-ready asset portfolio from a European biotech firm in July 2025; and the launch of a new manufacturing facility in Q4 2025 to accelerate MRPI-251 toward FDA submission, marking a significant expansion in operational capacity.